[¼ö¿ë°³ÀÛ]

1. ¼ö¿ë°³ÀÛÀ̶õ?

1. Áø·áÁöħ °³¹ßÀÇ ±Ù°Å°¡ µÇ´Â ¿¬±¸ÀÇ ´ëºÎºÐÀÌ ¿Ü±¹¿¡¼­ ½ÃÇàµÈ °ÍÀ̶ó¸é ±»ÀÌ Áø·áÁöħÀ» ÀÚü °³¹ßÇÒ ÇÊ¿ä°¡ ÀÖ´ÂÁö¿¡ ´ëÇÑ Àǹ®ÀÌ Á¦±âµÉ ¼ö ÀÖ´Ù. Àå±âÀûÀ¸·Î ±¹³» ¿¬±¸°¡ È°¼ºÈ­µÇ¸é, À̸¦ ±Ù°Å·Î Áø·áÁöħÀ» °³¹ßÇÏ´Â °ÍÀÌ Å¸´çÇÒ °ÍÀÌ´Ù. ÇÏÁö¸¸ ´Ü±âÀûÀ¸·Î´Â ¿Ü±¹¿¡¼­ °³¹ßµÈ ±âÁ¸ Áø·áÁöħÀÇ ÁúÀ» Æò°¡ÇÏ¿© ÁÁÀº Áø·áÁöħÀ» ¼ö¿ëÇÏ´Â °ÍÀÌ º¸´Ù È¿À²ÀûÀÏ ¼ö ÀÖ´Ù.

2. ¿Ü±¹ Áø·áÁöħÀ» ¼ö¿ëÇÒ ¶§¿¡µµ ¿øÄ¢°ú ÀýÂ÷°¡ ÀÖ´Ù. Áï °ø½ÄÀûÀÎ ¹æ¹ý·ÐÀ» »ç¿ëÇØ¾ß ÇÑ´Ù´Â °ÍÀÌ´Ù. ÇöÀç °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ¹æ¹ý·ÐÀº APAPTEÀÌ´Ù.

3. Research question (RQ)À» ¼³Á¤ÇÑ ÈÄ ÁúÁÁÀº ÇØ¿Ü Áø·áÁöħÀ» ¼Ò¼ö ¼±Á¤ÇÑ ÈÄ ±¹³» »óȲ¿¡ ¸Â°Ô ±Ç°í¹®¾ÈÀ» ¼ö¿ëÇÏ¿© °³ÀÛÇÑ´Ù. ¼ö¿ë°³ÀÛ¿¡´Â °ü·Ã Àü¹®°¡, ÀÌÇØ´ç»çÀÚÀÇ consensus°¡ ¸Å¿ì Áß¿äÇÏ´Ù.

4. ¼ö¿ë°³ÀÛÀ» Çϸ鼭 Áß¿äÇÑ ÇÇÄÚ¿¡ ´ëÇÑ ÀÚ·á°¡ ¾øÀ¸¸é De Novo ¹æ¹ý·ÐÀ» Ãß°¡ÇÏ´Â ¼ö ¹Û¿¡ ¾ø´Ù. ±¹³» Çö½Ç¿¡¼­´Â µÎ °¡Áö ¹æ¹ý·ÐÀÌ À¶ÇյǾî¾ß ÇÑ´Ù°í º»´Ù. ±×·¯³ª ¾ÆÁ÷±îÁö µÎ ¹æ¹ýÀ» À¶ÇÕÇÏ´Â °Í¿¡ ´ëÇÑ ¹æ¹ý·ÐÀÌ Á¦½ÃµÈ ¹Ù ¾ø´Ù.

¼ö¿ë°³ÀÛ ¹æ¹ý·Ð(WORD ¹®¼­)


2. ¼ö¿ë°³ÀÛÀÇ ¿øÄ¢

1. ±Ù°ÅÁß½ÉÀ¸·Î ÀÌ·ç¾îÁ®¾ß ÇÑ´Ù.

2. ½Å·Úµµ°¡ ³ô°í ÀÏ°ü¼ºÀÌ ÀÖ´Â ¹æ¹ýÀ¸·Î ÁøÇàµÇ¾î¾ß ÇÑ´Ù.

3. ÇÙ½ÉÀûÀÎ ÀÌÇØ ´ç»çÀÚ°¡ ¸ðµÎ Âü¿©ÇØ¾ß ÇÑ´Ù.

4. Àû¿ëµÇ´Â ½ÇÁ¤(context)À» ¸íÈ®ÇÏ°Ô ¹Ý¿µÇÏ°í °í·ÁÇÏ¿©¾ß ÇÑ´Ù.

5. Åõ¸íÇÏ°Ô ÁøÇàÇÏ°í º¸°íÇÏ¿©¾ß ÇÑ´Ù.

6. ƯÁ¤ÇÑ ¿ä±¸³ª »óȲÀ» ¼ö¿ëÇÒ ¼ö ÀÖ´Â À¯¿¬¼º ÀÖ´Â Çü½ÄÀ» °®Ãß¾î¾ß ÇÑ´Ù.

7. ¿ø Áø·áÁöħÀÇ ÃëÁö³ª ³»¿ëÀÌ ÈѼյÇÁö ¾Êµµ·Ï Ã¥ÀÓ¼ºÀ» °¡Á®¾ß ÇÑ´Ù.


3. ¼ö¿ë°³ÀÛÀ» À§ÇÑ À§¿øȸ ±¸¼º]

1. Áø·áÁöħ Á¶Á÷À§¿øȸ (Organizing committee): »ç¾÷°èȹ, °³¹ßÀü·« ³íÀÇ, ÁÖÁ¦ ¼±Á¤, Áø·áÁöħ °³¹ßÀ§¿øȸ À§¿øÀå ¼±ÀÓ, ¼öÁ¤µÈ ±Ç°í»çÇ× °ËÅä, ÃÖÁ¾ Áöħ ½ÂÀÎ ¹× ÃâÆÇ

2. Áø·áÁöħ °³¹ßÀ§¿øȸ (guideline development group: GDG): °³¹ß°èȹ, °³¹ß°úÁ¤, °ËÅä ¹× ¼öÁ¤, °³Á¤, ¹ßÇà ¹× ¹èÆ÷, ½ÇÇà

3. Áø·áÁöħ °¨¼öÀ§¿øȸ (guideline review committee)


4. ¼ö¿ë°³ÀÛ °úÁ¤]

°¡Àå º¸ÆíÀûÀÎ ´Ü°è´Â ¾Æ·¡¿Í °°Àº ADAPTE°úÁ¤ÀÌ´Ù. ADAPTE °úÁ¤Àº 3ºÎ, 9¸ðµâ, 23´Ü°è·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. (source: NECA ¼ö¿ë°³ÀÛ ¸Å´º¾ó)

1. ¹üÀ§¿Í PICO(H) Çü½Ä¿¡ µû¸¥ ÇÙ½ÉÁú¹® °áÁ¤ -- ÀÌ ´Ü°è¿¡¼­ 1Â÷ ÇÕÀÇ¾È µµÃâÀ» À§ÇÑ questioning °úÁ¤À» °ÅÄ¡´Â °ÍÀÌ ÁÁ´Ù

2. key word¸¦ ÀÌ¿ëÇÏ¿© ÁöħÀ» ã±â -- Medline, EMBASE µî

3. Æ÷ÇÔ±âÁØ, ¹èÁ¦±âÁØÀ» ÀÌ¿ëÇÏ¿© 1Â÷ screening -- 10°³ ¹Ì¸¸ÀÇ ÁöħÀ» ¼±Á¤

4. AGREE II¸¦ ÀÌ¿ëÇÏ¿© 2Â÷ screening -- 5-6°³ ¹Ì¸¸ÀÇ ÁöħÀ» ¼±Á¤

5. ¹Ì¸® Á¤ÇصР±âÁØ¿¡ µû¶ó ÃÖÁ¾ Áöħ ¼±Á¤ -- 2-3°³ Á¤µµ

6. ÁöħÀÇ ±Ç°í¹®¾ÈÀ» ºÐ¼®ÇÏ¿© ±Ç°í¹®¾È matrix ÀÛ¼º -- source guideline ¹× ±Ù°Å¼öÁØ Ç¥±â

7. ÇÕÀÇÇÑ µµÃâ: (Modified) Delphi technique (ȤÀº NGT, nominal group technique)¸¦ ÀÌ¿ëÇÏ¿© Áöħ ±Ç°í¹®¾È ¼öÁ¤


5. PICOHÀÇ ¿¹

1. Á¦¸ñ ºÐ·ù: Endoscopic treatment

2. Áú¹®: ÃâÇ÷±Ë¾çÀÇ ±âÀúºÎ¿¡ ºÙ¾îÀÖ´Â Ç÷±«´Â Ç÷±« ¹ØÀÇ º´º¯À» Ä¡·áÇϱâ À§ÇØ Á¦°ÅÇؾßÇϴ°¡?

- P: ÃâÇ÷±Ë¾çÀÇ ±âÀúºÎ¿¡ Ç÷±«°¡ Àִ ȯÀÚ

- I: Ç÷±«Á¦°Å ÈÄ ³»½Ã°æÀû Ä¡·á

- C: Ç÷±«¸¦ Á¦°ÅÇÏÁö ¾ÊÀ½

- O: ÃâÇ÷·ü

- H: ÀÔ¿ø


6. ü°èÀû Áø·áÁöħ °Ë»ö flowchart »ç·Ê

´Ù¾çÇÑ º¯ÇüÀÌ °¡´ÉÇÏÁö¸¸ º¸Åë ¾Æ·¡ÀÇ 4 °¡Áö¸¦ Æ÷ÇÔÇÏ´Â °ÍÀÌ ÁÁ´Ù.

1. Identification

2. Screening

3. Eligibility

4. Included


http://qualitysafety.bmj.com/content/19/6/1.63.full


7. AGREE-II¸¦ ÀÌ¿ëÇÑ Æò°¡ÀÇ ¿¹


AGREE-II¸¦ È°¿ëÇϱâ À§ÇÑ fill-up¿ë Excel spreadsheet


AGREE-II·Î Æò°¡µÈ ³í¹®À» ¿µ¿ªº°·Î Æò°¡Çϱâ À§ÇÑ ±×·¡ÇÁ


AGREE¸¦ ÀÌ¿ëÇÑ Æò°¡°á°ú ¿ä¾à (NECAÀÇ ¼ö¿ë°³ÀÛ ¸Å´º¾ó¿¡¼­ °¡Á®¿È)

°³¹ßÀÇ ¾ö°Ý¼º 50% ÀÌ»ó


8. Áø·áÁöħ ¼±Á¤ÀÇ ¿¹ (2013³â Ç︮ÄÚ¹ÚÅÍ °¡À̵å¶óÀÎ)

2012³â 7¿ù

- Áø·áÁöħ °Ë»ö ÀÚ·á¿ø 1 (±¹¿Ü) Medline, Medline Systemic Review, Medline Clinical Study, Ovid Medline, EMBASE, Web of Science, Cochrane Library

- Áø·áÁöħ °Ë»ö ÀÚ·á¿ø 2 (±¹³») KoreaMed, KmBase, RISS

- Áø·áÁöħ °Ë»ö ÀÚ·á¿ø 3 (±âŸ) Google Scholar, Scopus, ¹Ì±¹ National Guideline Clearinghouse, ±¹Á¦Áø·áÁöħÀ§¿øȸ GINÀÇ International Guideline Library, ij³ª´Ù CMA Infobase


1. Search in electronic databases: 2224°³

2. Irrelevant citations excluded after checking for title and abstract and removal of duplications »« ÈÄ: 1482°³

3. Not relevant in evaluation »« ÈÄ: 45°³

4. Inclusion°ú exclusion criteria¿¡ µû¸¥ Æò°¡ ÈÄ :6°³

ÃÖÁ¾ ¼±Á¤µÈ 6°³: 2004 Canadian, 2007 American College of Gastroenterology, 2009 ´ëÇѹα¹, 2009 Japan, 2009 Asia-Pacific, 2012 Maastricht


9. ±Ç°í¹®¾È matrix ¿¹Á¦


10. ÃÖÁ¾ Áø·áÁöħ¿¡ Æ÷ÇԵǾî¾ß ÇÒ ³»¿ë

1. Acknowledgements: funding, guideline development group, patient involvement, stakeholder groups, Delphi panelists

2. Index of contents

3. Introduction

4. Aims

5. Scope

6. Guideline methodology: 1) Clinical (research) questions, 2) Participants of (or PICO), 3) Inclusion & exclusion criteria, 4) Level of evidence & strength of recommendation, 5) Evidence (or guidelines) search & appraisal (AGREE II), 6) Delphi consensus process, 7) Economic evaluation, 8) Good practice points, 9) Recommendation formation, 10) Review process, 11) Guideline recommendations with explanations, 12) Guideline algorithm, 12) Implementation strategy, 13) Audit, 14) Research points, 15) Update process, 16) References

7. Appendice: 1) Evidence table, 2) Guideline group meeting, 3) Delphi consensus results, 4) Stakeholder involvement, 5) Patient participation, 6) Editorial independence


11. More readings

1. APAPTE toolkit (2009) (link2)

2. ¼ö¿ë°³ÀÛ ¸Å´º¾ó (NECA) (link2)

3. ¿Ü±¹ÀÇ ÀÓ»óÁø·áÁöħ °³ÀÛ ÇöȲ (µ¿±¹ÀÇ´ë ±è³²¼ø ±³¼ö) (link2)

4. Graham and Harrison. Evaluation and adaptation of clinical practice guidelines (2005) - (link2)

5. Adaptation of clinical guidelines: a review (link2)

6. Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation.BMJ Qual Saf. 2011 Mar;20(3):228-36

7. The process of NCCN guidelines adaptation to the Middle East and North Africa region

8. ¼ö¿ë°³ÀÛ ¹æ¹ý·Ð(WORD ¹®¼­)

[Home]